Enantioselective binding of Casodex to the androgen receptor

Xenobiotica

Volumn 26, Issue 2, 1996, Pages 117-122

  Mukherjee, A ^a   Kirkovsky, L ^a   Yao, X T ^a   Yates, R C ^a   Miller, D D ^a   Dalton, J T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; MIBOLERONE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; IN VITRO STUDY; ISOMER; MALE; NONHUMAN; PROSTATE; RAT; STEREOISOMERISM; STEREOSPECIFICITY;

ANIMALIA;

EID: 0029863106     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046693     Document Type: Article

References (13)

1. CARLSON, K. E., and KATZENELLENBOGEN, J. A., 1990, A comparative study of the selectivity and efficiency of target tissue uptake of five tritium-labelled androgens in the rat. Journal of Steroid Biochemistry, 36, 549-561.
2. COCKSHOTT, I. D., PLUMMER, G. F., COOPER, K. J., and WARWICK, M. J., 1991, The pharmacokinetics of Casodex in laboratory animals. Xenobiotica, 21, 1347-1355.
3. DENIS, L., and MAHLER, C., 1990, Prostatic cancer: an overview. Acta Oncologica, 29, 665-677.
4. HECHTER, O., MECHABER, D., ZWICK, A., CAMPFIELD, A. C., EYCHENNE, B., BAULIEU, E.-E., and ROBEL, P., 1983, Optimal radioligand exchange conditions for measurement of occupied androgen receptor sites in rat ventral prostate. Archives of Biochemistry and Biophysics, 224, 49-68.
5. KENNEALEY, G. T., and FURR, B. J. A., 1991, Use of the non-steroidal antiandrogen Casodex in advanced prostatic carcinoma. Urologic Clinics of North America, 18, 99-110.
6. LABRIE, F., 1991, Endocrine therapy for prostate cancer. Endocrinology and Metabolism Clinics of North America, 20, 845-872.
7. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L., and RANDALL, N. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265.
8. MCCONNELL, J. D., 1991, Physiologic basis of endocrine therapy for prostatic cancer. Urologic Clinics of North America, 18, 1-13.
9. MCKILLOP, D., BOYLE, G. W., COCKSHOTT, I. D., JONES, D. C., PHILLIPS, P. J., and YATES, R. A., 1993, Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica, 23, 1241-1253.
10. SOLOWAY, M. S., and MATZKIN, H., 1993, Antiandrogenic agents as monotherapy in advanced prostatic cancer. Cancer, 71 (suppl. 3), 1083-1088.
11. TUCKER, H., and CHESTERSON, G. J., 1988, Resolution of the non-steroidal antiandrogen 4′-Cyano-3-[(4-flurophenyl)sulfonyl)]-2-hydroxy-2-methyl-3′- (trifluromethyl)-propioanilide and determination of the absolute configuration of the active enantiomer. Journal of Medical Chemistry, 31, 885-887.
12. TUCKER, H., CROOK, J. W., and CHESTERSON, G. J., 1988, Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropioanilides. Journal of Medical Chemistry, 31, 954-959.
13. VELDSCHOLTE, J., BERREVOETS, C. A., RIS-STALPERS, C., KUIPER, G. G. J. M., JENSTER, G., TRAPMAN, J., BRINKMANN, A. O., and MULDER, E., 1992, The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. Journal of Steroid Biochemistry and Molecular Biology, 41, 665-669.